Literature DB >> 2861920

Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon.

J D Coffman, H M Rasmussen.   

Abstract

Digital vasospastic phenomena have been reported to result from use of nonselective and cardioselective beta-adrenoreceptor-blocking drugs. The effects of 80 mg/day propranolol and 100 mg/day metoprolol on finger hemodynamics and clinical responses were compared with those of placebo in 16 patients with Raynaud's phenomenon. A double-blind, 2 week crossover study design was used with a 2 week washout placebo period between drugs. Total fingertip blood flow (FBF) as determined by venous occlusion plethysmography, fingertip capillary flow (FCF) as determined by radioisotope disappearance rate, and finger systolic blood pressure (FSP) were measured in a 28.3 degrees and a 20 degrees C room at the end of each period. Subjects kept diaries to record vasospastic attacks. There were no significant changes in FBF, FCF, or FSP in the warm or cool environment during drug treatment as compared with during the placebo period. A decrease in pulse rate occurred with both drugs and there was a decrease in blood pressure with metoprolol. There were no significant changes in the number of vasospastic attacks or in the patients' overall evaluation of their conditions while they were receiving the drugs. It is concluded that the presence of Raynaud's phenomenon is not a contraindication to the use of beta-adrenoreceptor-blocking drugs in the normotensive population.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861920     DOI: 10.1161/01.cir.72.3.466

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

4.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 5.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 6.  Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.

Authors:  Charles Khouri; Thomas Jouve; Sophie Blaise; Patrick Carpentier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

Review 7.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 8.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Secukinumab-induced Raynaud's phenomenon: first report in the literature.

Authors:  Senol Kobak
Journal:  Ther Adv Drug Saf       Date:  2020-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.